EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A new fluorescenttargeting tracer contrasts dual tracers in sentinel lymph node biopsy of breast cancer

Shuang Wu iD, Panpan Li, Qingsong Zhang, Xiao Sun, Binbin Cong, Yongsheng Wang

Future Oncology · 2024

DOI: 10.2217/fon-2021-1152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Oncology, 2024. Verfasst von Shuang Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: General Surgery, Kailuan General Hospital, Tangshan, Heibei, 063000, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Sentinel Lymph Node. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To explore the clinical application value of indocyanine green (ICG)-rituximab in sentinel lymph node biopsy.

Methods

This study included 156 patients with primary breast cancer: 50 patients were enrolled in dose-climbing test, and 106 patients were enrolled in verification test. This was to compare the consistency of ICG-rituximab and combined method in the detected lymph nodes.

Results

According to the verification test, the imaging rate of ICG-rituximab was 97.3%. Compared with the combined method, the concordance rate of fluorescence method was 0.991 (28 + 78/107; p < 0.001).

Conclusion

For ICG-rituximab as a fluorescent targeting tracer, the optimal imaging dose of ICG 93.75 μg/rituximab 375 μg can significantly reduce the imaging of secondary lymph nodes. Compared with the combined method, it has a higher concordance rate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsSentinel Lymph NodeHumansFemaleSentinel Lymph Node BiopsyRituximabColoring AgentsIndocyanine GreenLymph NodesContrast Media

Stichwörter der Autor:innen

ICGICG–rituximabSLNBbreast cancerdose-climbing testfluorescent targeting tracerrituximabsentinel lymph nodetracerverification test

Substanzen

RituximabColoring AgentsIndocyanine GreenContrast Media

Autor:innen und Institutionen

  • General Surgery, Kailuan General Hospital, Tangshan, Heibei, 063000, China.
  • Department of Breast Surgery, Yuncheng Central Hospital, Yuncheng, 044000, China.
  • Breast Cancer Center, Shandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Science, Jinan, 250000, China.

ORCID-Profile: Shuang Wu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wu, S., Li, P., Zhang, Q., Sun, X., Cong, B., & Wang, Y. (2024). A new fluorescenttargeting tracer contrasts dual tracers in sentinel lymph node biopsy of breast cancer. Future Oncology. https://doi.org/10.2217/fon-2021-1152

Vancouver

Wu S, Li P, Zhang Q, Sun X, Cong B, Wang Y. A new fluorescenttargeting tracer contrasts dual tracers in sentinel lymph node biopsy of breast cancer. Future Oncology. 2024. doi:10.2217/fon-2021-1152

BibTeX
@article{Wu2024,
  author = {Wu, Shuang and Li, Panpan and Zhang, Qingsong and Sun, Xiao and Cong, Binbin and Wang, Yongsheng},
  title = {A new fluorescenttargeting tracer contrasts dual tracers in sentinel lymph node biopsy of breast cancer},
  journal = {Future Oncology},
  year = {2024},
  doi = {10.2217/fon-2021-1152}
}
Kostenlos starten →